{"id":50292,"date":"2026-09-17T21:19:44","date_gmt":"2026-09-17T21:19:44","guid":{"rendered":"https:\/\/allonlinebanglanewspapers.com\/news\/onco360-has-been-selected-as-a-national-pharmacy-partner-for-etcamah-camizestrant\/"},"modified":"2026-09-17T21:19:44","modified_gmt":"2026-09-17T21:19:44","slug":"onco360-has-been-selected-as-a-national-pharmacy-partner-for-etcamah-camizestrant","status":"publish","type":"post","link":"https:\/\/allonlinebanglanewspapers.com\/news\/onco360-has-been-selected-as-a-national-pharmacy-partner-for-etcamah-camizestrant\/","title":{"rendered":"Onco360\u00ae Has Been Selected as a National Pharmacy Partner for ETCAMAH\u2122 (camizestrant)"},"content":{"rendered":"

LOUISVILLE, Ky., Sept. 17, 2026 (GLOBE NEWSWIRE)<\/a> — Onco360\u00ae<\/sup>, the nation\u2019s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by AstraZeneca for Etcamah\u2122\u00a0(camizestrant), which is indicated for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of\u00a0ESR1<\/em>\u00a0mutation during aromatase inhibitor (AI) and CDK4\/6 inhibitor therapy, based on a US Food and Drug Administration (FDA)-authorized test.1<\/sup><\/p>\n

“The approval of Etcamah represents an important advancement in cancer care, bringing renewed hope and a meaningful new treatment option for breast cancer patients. Onco360 is honored to expand our partnership with AstraZeneca by providing access to this innovative therapy in support of the patients and caregivers we serve,\u201d said Benito Fernandez, Chief Commercial Officer.<\/p>\n

Etcamah is an estrogen receptor (ER) antagonist. In vitro, Etcamah binds to the ligand-binding domain of ER\u03b1, antagonizing the activity of ER\u03b1 encoded by both wild-type ESR1 and mutated ESR1 and inducing proteasome-dependent degradation of ER\u03b1, without agonizing ER\u03b1.1<\/sup>\u00a0\u00a0<\/p>\n

Etcamah\u2019s approval was based on the phase 3 SERENA-6 study (NCT04964934), an open-label, randomized trial, evaluating Etcamah in combination with a CDK4\/6 inhibitor, which reduced the risk of disease progression or death by 56% versus standard-of-care treatment with an AI (anastrozole or letrozole) in combination with a CDK4\/6 inhibitor. 2<\/sup> The median PFS was 16 months vs 9.2 months; HR 0.44 (95% CI 0.31\u20130.60). The most common (\u2265 20%) adverse reactions, including laboratory abnormalities, were decreased neutrophils, decreased leukocytes, decreased hemoglobin, decreased lymphocytes, decreased platelets, visual disturbances, and fatigue.1<\/sup><\/p>\n

Please read the full prescribing information<\/a> for Etcamah.<\/p>\n

About Onco360 Oncology Pharmacy<\/strong><\/p>\n

Onco360 is the nation\u2019s largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Onco360.com<\/a>.<\/p>\n

Media Contact: Benito Fernandez, Chief Commercial Officer
Benito.Fernandez@onco360.com<\/a>
516-640-1332<\/p>\n

References: <\/strong><\/p>\n

1<\/sup>Etcamah\u2122 (camizestrant) [Package Insert]. Wilmington, DE. AstraZeneca Pharmaceuticals. 2026.<\/p>\n

2<\/sup>Bidard, FC, et al. First-Line Camizestrant for Emerging\u00a0ESR1<\/em>-Mutated Advanced Breast Cancer. N Engl J Med. 2025 Aug 7;393(6):569-580. doi: 10.1056\/NEJMoa2502929. Epub 2025 Jun 1. PMID: 40454637.<\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

LOUISVILLE, Ky., Sept. 17, 2026 (GLOBE NEWSWIRE) — Onco360\u00ae, the nation\u2019s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by AstraZeneca for Etcamah\u2122\u00a0(camizestrant), which is indicated for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of\u00a0ESR1\u00a0mutation during aromatase inhibitor (AI) and […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[11],"tags":[],"class_list":["post-50292","post","type-post","status-publish","format-standard","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t